Y-mAbs Therapeutics Inc. (YmAbs) is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer based on a range of technologies licensed from Memorial Sloan Kettering Cancer Center. Its mission is to become the world leader in developing better and safer antibody-based pediatric oncology products addressing clear unmet medical needs. YmAbs also seeks to advance and expand its product pipeline into certain adult cancer indications and to leverage its extensive drug development capabilities and platform technology towards the creation of new types of bispecific antibodies.
Copyright West LLC. Minimum 15 minutes delayed.
Dec 13, 2018Y-mAbs Therapeutics To Present At 37th Annual J.P. Morgan Healthcare Conference
Dec 11, 2018Y-mAbs Announces Appointment of Gérard Ber to its Board of Directors and Planned Departure of Michael Buschle
Dec 10, 2018Y-mAbs Therapeutics Announces FDA Clearance of IND for its Bispecific GD2 Antibody
More events are coming soon.